BioCentury | Jul 10, 2020
Finance

2Q20 Wrap: Biotech bounce

...biggest drop came from a member of the 2Q20 IPO class, in vitro diagnostics company Progenity Inc....
...teprotumumab (HZN-001, RV001, r1507, rg1507) Moderna Inc. Horizon Therapeutics plc Inovio Pharmaceuticals Inc. Novavax Inc. Celldex Therapeutics Inc. Biogen Inc. Novocure Ltd. NextCure Inc. Progenity Inc. Newron...
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

...see “First Broad Deal With BMS” ). Also pricing were Genetron Holdings Ltd. (NASDAQ:GTH) and Progenity Inc....
...designed to target Chinese companies (see “Bill Could Deter Chinese Biotechs from U.S. Listings” ). Progenity’s...
...develops in vitro molecular tests including prenatal screens and women’s health tests, still met expectations; Progenity...
BioCentury | Jun 17, 2020
Finance

Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

...companies in the queue moved closer to their debuts: Repare Therapeutics Inc., Forma Therapeutics Inc., Progenity Inc....
...midpoint, the synthetic lethality play would raise $125 million and be valued at $535.6 million. Progenity...
...valuation of $677.5 million. Elizabeth S. Eaton, Staff Writer Royalty Pharma plc Repare Therapeutics Inc. Forma Therapeutics Inc. Genetron Holdings Ltd. Progenity Inc. IPO...
BioCentury | Jun 3, 2020
Finance

Daily Chart: IPO queue grows to 20 life sciences companies

...Frenzy” ). Elizabeth S. Eaton, Staff Writer Pliant Therapeutics Inc. Lantern Pharma Inc. Legend Biotechnology Co. Ltd. Applied Molecular Transport Inc Progenity Inc. Forma...
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

...warrants at $4.50 each, an 11% discount to Wednesday’s $5.04 close. Progenity planning NASDAQ listing Progenity Inc....
...4 S1P - Sphingosine 1-phosphate Robin Sawka, BioCentury Staff Illumina Ginkgo Bioworks Inc. Arena Pharmaceuticals Inc. Viela Bio Inc. BioCryst Pharmaceuticals Inc. Progenity Inc. Microbion...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...Johnson & Johnson (NYSE:JNJ); she was director of healthcare at INKEF Capital. Molecular testing company Progenity Inc....
...University Intellia Therapeutics Inc. Cortexyme Inc. Chan Zuckerberg Biohub Grail Inc. PMV Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. Gritstone Oncology Inc. PCI Biotech Holding ASA Progenity Inc. Galecto...
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said EVP and CFO Shalini Sharp will step down by Sept. 2 to focus on serving as an adviser and board member for various biotech companies. Sharp will remain with the...
BioCentury | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

Theravance gains $10M upfront in Pfizer deal Theravance Biopharma Inc. (NASDAQ:TBPH) granted Pfizer Inc. (NYSE: PFE) exclusive, worldwide rights to its skin-targeted, locally-acting pan-JAK inhibitor program for undisclosed skin conditions. Theravance will receive $10 million...
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
BioCentury | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

Miles White will step down as CEO of Abbott Laboratories (NYSE:ABT) on March 31, after 21 years in the role while remaining executive chairman. President and COO Robert Ford, who joined the company in 1996,...
Items per page:
1 - 10 of 724
BioCentury | Jul 10, 2020
Finance

2Q20 Wrap: Biotech bounce

...biggest drop came from a member of the 2Q20 IPO class, in vitro diagnostics company Progenity Inc....
...teprotumumab (HZN-001, RV001, r1507, rg1507) Moderna Inc. Horizon Therapeutics plc Inovio Pharmaceuticals Inc. Novavax Inc. Celldex Therapeutics Inc. Biogen Inc. Novocure Ltd. NextCure Inc. Progenity Inc. Newron...
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

...see “First Broad Deal With BMS” ). Also pricing were Genetron Holdings Ltd. (NASDAQ:GTH) and Progenity Inc....
...designed to target Chinese companies (see “Bill Could Deter Chinese Biotechs from U.S. Listings” ). Progenity’s...
...develops in vitro molecular tests including prenatal screens and women’s health tests, still met expectations; Progenity...
BioCentury | Jun 17, 2020
Finance

Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

...companies in the queue moved closer to their debuts: Repare Therapeutics Inc., Forma Therapeutics Inc., Progenity Inc....
...midpoint, the synthetic lethality play would raise $125 million and be valued at $535.6 million. Progenity...
...valuation of $677.5 million. Elizabeth S. Eaton, Staff Writer Royalty Pharma plc Repare Therapeutics Inc. Forma Therapeutics Inc. Genetron Holdings Ltd. Progenity Inc. IPO...
BioCentury | Jun 3, 2020
Finance

Daily Chart: IPO queue grows to 20 life sciences companies

...Frenzy” ). Elizabeth S. Eaton, Staff Writer Pliant Therapeutics Inc. Lantern Pharma Inc. Legend Biotechnology Co. Ltd. Applied Molecular Transport Inc Progenity Inc. Forma...
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

...warrants at $4.50 each, an 11% discount to Wednesday’s $5.04 close. Progenity planning NASDAQ listing Progenity Inc....
...4 S1P - Sphingosine 1-phosphate Robin Sawka, BioCentury Staff Illumina Ginkgo Bioworks Inc. Arena Pharmaceuticals Inc. Viela Bio Inc. BioCryst Pharmaceuticals Inc. Progenity Inc. Microbion...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

...Johnson & Johnson (NYSE:JNJ); she was director of healthcare at INKEF Capital. Molecular testing company Progenity Inc....
...University Intellia Therapeutics Inc. Cortexyme Inc. Chan Zuckerberg Biohub Grail Inc. PMV Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. Gritstone Oncology Inc. PCI Biotech Holding ASA Progenity Inc. Galecto...
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said EVP and CFO Shalini Sharp will step down by Sept. 2 to focus on serving as an adviser and board member for various biotech companies. Sharp will remain with the...
BioCentury | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

Theravance gains $10M upfront in Pfizer deal Theravance Biopharma Inc. (NASDAQ:TBPH) granted Pfizer Inc. (NYSE: PFE) exclusive, worldwide rights to its skin-targeted, locally-acting pan-JAK inhibitor program for undisclosed skin conditions. Theravance will receive $10 million...
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
BioCentury | Nov 14, 2019
Company News

Management tracks: Longtime Abbott CEO resigning; plus Otsuka, Bavarian Nordic, Progenics and Rakuten

Miles White will step down as CEO of Abbott Laboratories (NYSE:ABT) on March 31, after 21 years in the role while remaining executive chairman. President and COO Robert Ford, who joined the company in 1996,...
Items per page:
1 - 10 of 724